{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:22:45Z","timestamp":1767046965633},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2020,7,20]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Highly active antiretroviral therapy (HAART), especially tenofovir DFcontaining\nregimens, has been implicated in albuminuria.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>We prospectively evaluated the effects of HAART on albumin-to-creatinine ratios\n(ACRs) in antiretroviral-na\u00efve HIV-infected individuals.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title> Methods:<\/jats:title>\n<jats:p>One hundred and two (102) newly diagnosed, antiretroviral-na\u00efve, human immunodeficiency\nvirus (HIV)-infected persons were treated with Tenofovir disoproxil fumarate\/\nEmtricitabine\/Efavirenz (TDF\/FTC\/EFV), n=33; Zidovudine\/Lamivudine\/Nevirapine\n(ZDV\/3TC\/NVP), n=53; and Zidovudine\/Lamivudine\/Efavirenz (ZDV\/3TC\/EFV), n=16. Diabetes\nmellitus and hypertension were excluded. ACRs and glomerular filtration rates (eGFR) were estimated\nat baseline, and at 1, 3, 6 and 9 months post-therapy; the prevalence of albuminuria (ACR \u2265\n300mg\/g), and microalbuminuria (ACR 30-300mg\/g) were similarly estimated. HAART effects\non normal ACR (0-30mg\/g) were also monitored.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>At baseline, one patient (0.9%) had nephrotic-range albuminuria with ACR of 2450mg\/g.\nOverall, 8 (7.8%) patients had albuminuria; 53 (51.9%) had microalbuminuria; while 41 (40.2%)\nhad normal ACRs, 28 (27.5% of 102) of which had nonalbuminuric renal insufficiency. eGFR and\nACRs improved concurrently on HAART (ACR, Wilks\u2019 lambda 0.439, power 0.763, p=0.032);\nalbuminuria improved significantly on all the 3 regimens at 9 months (p=0.006, 0.012 and &lt;0.001\nrespectively). Microalbuminuria resolved earlier (1 month) with ZDV\/3TC\/NVP than with\nTDF\/FTC\/EFV and ZDV\/3TC\/EFV (24.31mg\/g versus 76.51mg\/g and 63.59mg\/g; p=0.028, 0.016\nrespectively). Microalbuminuria relapsed on TDF\/FTC\/EFV and ZDV\/3TC\/EFV at 6 months but\nresolved again at 9 months (66.7 versus 29 mg\/g, p=0.006; and 51.2 versus 9.5mg\/g, p=0.001 respectively);\nno relapse on ZDV\/3TC\/NVP. At 9 months, ZDV\/3TC\/EFV caused the greatest resolution\nof microalbuminuria (85.7% decline in ACR from baseline) compared with ZDV\/3TC\/NVP\n(72.5% decline) and TDF\/FTC\/EFV (63.9% decline). In multivariate analyses, predictors of ACR\ninclude older age (Odds ratio OR 2.8, p= 0.025); female gender (OR, 3.4, p =0.014); CD4+ (OR\n0.99, p=0.002).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>HIV induces renal impairment. Thus, albuminuria, microalbuminuria and nonalbuminuric\nrenal insufficiency are highly prevalent in antiretroviral-na\u00efve HIV-infected persons but\nnephrotic-range albuminuria is uncommon. Albuminuria and\/microalbuminuria and eGFR improve\nconcurrently on HAART (with\/without tenofovir DF). Zidovudine-based HAART\n(ZDV\/3TC\/NVP) resolves microalbuminuria earlier, and without relapse, unlike Tenovofir-based\nregimen and zidovudine with efavirenz (ZDV\/3TC\/EFV).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526519666190807155025","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T12:25:53Z","timestamp":1565180753000},"page":"374-384","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIV-infected Persons"],"prefix":"10.2174","volume":"20","author":[{"given":"Tewogbade Adeoye","family":"Adedeji","sequence":"first","affiliation":[{"name":"Department of Chemical Pathology, Obafemi Awolowo, University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simeon Adelani","family":"Adebisi","sequence":"additional","affiliation":[{"name":"Department of Chemical Pathology, Benue State University, Makurdi, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nife Olamide","family":"Adedeji","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, University Teaching Hospitals Complex, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/174164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T07:24:17Z","timestamp":1600845857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/174164\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526519666190807155025","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}